Abstract: The present disclosure relates to a dopamine stabilizing agent and an anti-depressive agent for use in the treatment of disorders characterized by debilitating fatigue, such as myalgic encephalomyelitis (ME)/Chronic fatigue syndrome (CFS), fibromyalgia (FM) and depression, as well as of combinations thereof. Related treatment methods, pharmaceutical compositions and combination kits are also disclosed.

Abstract: The present disclosure relates to a dopamine stabilizing agent and an anti-depressive agent for use in the treatment of disorders characterized by debilitating fatigue, such as myalgic encephalomyelitis (ME)/Chronic fatigue syndrome (CFS), fibromyalgia (FM) and depression, as well as of combinations thereof. Related treatment methods, pharmaceutical compositions and combination kits are also disclosed.

Abstract: The present disclosure relates to a dopamine stabilizing agent and an anti-depressive agent for use in the treatment of disorders characterized by debilitating fatigue, such as myalgic encephalomyelitis (ME)/Chronic fatigue syndrome (CFS), fibromyalgia (FM) and depression, as well as of combinations thereof. Related treatment methods, pharmaceutical compositions and combination kits are also disclosed.

Abstract: The present disclosure relates to a dopamine stabilizing agent and an anti-depressive agent for use in the treatment of disorders characterized by debilitating fatigue, such as myalgic encephalomyelitis (ME)/Chronic fatigue syndrome (CFS), fibromyalgia (FM) and depression, as well as of combinations thereof. Related treatment methods, pharmaceutical compositions and combination kits are also disclosed.

Abstract: The Invention relates to a procedure for the use of staphylococcal bacteria or a product derived therefrom. The aforementioned staphylococcal bacteria or a product derived therefrom are intended for the production of a pharmaceutical preparation for the treatment of and/or for the prevention of irritable bowel syndrome.

Abstract: The Invention relates to a procedure for the use of staphylococcal bacteria or a product derived therefrom. The aforementioned staphylococcal bacteria or a product derived therefrom are intended for the production of a pharmaceutical preparation for the treatment of and/or for the prevention of irritable bowel syndrome.

Abstract: Use of a staphylococcus bacteria or a product thereof for the manufacture of a pharmaceutical preparation for treatment and/or prevention of fibromylagia and chronic fatigue syndrome. Preferably, the preparation also comprises vitamin B12 and/or folacin. A method for treatment of and/or prevention of chronic fatigue syndrome or fibromylagia, characterized in that a staphylococcal preparation is administered in a therapeutically effective amount, preferably in combination with or parallel with vitamin B12 and/or folacin. The preparation is preferably administered repeatedly, first 8-10 times during a period of 4-12 weeks when the dose is increased from a relatively lower dose the first administration to a relatively higher dose the last administration, then approximately once a week for 5-15 weeks, and finally approximately once a month for a period of 1-10 years.